FY2025 · ended Dec 31, 2025 · Revenue $160.00M, +3.9% YoY · Filed Feb 25, 2026
Pacific Biosciences of California, Inc. (PACB) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $160.0 million and a net loss of $546.4 million. Free cash flow was -$113.9 million. As of Jun 30, 2026 it held $236.9 million in cash and investments and $61.8 million in total debt.
Revenue (TTM)
$159.27M
+2.0% vs year-ago TTM
Net income (TTM)
$-131.39M
+75.0% vs year-ago TTM
Operating cash flow (TTM)
$-118.05M
+21.1% vs year-ago TTM
Free cash flow (TTM)
$-123.42M
+19.0% vs year-ago TTM
EPS (TTM)
$-0.43
+75.3% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
302.00M
+1.4% vs prior year
Net cash
$175.08M
as of Jun 30, 2026
Operating margin
-83.5%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- PACB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1299130
- Former names
- PACIFIC BIOSCIENCES OF CALIFORNIA INC (until Feb 5, 2013); NANOFLUIDICS INC (until Jul 28, 2004)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $160.0M | $154.0M | $200.5M | $128.3M | $130.5M |
| Operating income | -$553.9M | -$474.3M | -$334.5M | -$307.2M | -$210.4M |
| Net income | -$546.4M | -$309.9M | -$306.7M | -$314.2M | -$181.2M |
| Diluted EPS | -$1.82 | -$1.59 | -$1.21 | -$1.40 | -$0.89 |
| Operating cash flow | -$111.2M | -$206.1M | -$259.2M | -$263.2M | -$111.2M |
| Free cash flow | -$113.9M | -$212.2M | -$268.0M | -$280.0M | -$117.1M |
| Total assets | $784.1M | $1.3B | $1.7B | $1.8B | $2.0B |
| Total liabilities | $778.7M | $753.9M | $1.0B | $1.2B | $1.2B |
| Stockholders' equity | $5.3M | $506.6M | $701.3M | $562.9M | $791.0M |
| Cash and investments | $279.5M | $389.9M | $727.5M | $842.2M | $1.2B |
| Total debt | $57.0M | $24.9M | $41.7M | $948.5M | $953.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 4, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change, Regulation FD disclosure
|
Aug 5, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 9, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 971 Pacific Biosciences of California, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.